STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Pharmaceuticals
drugs-2

Regenxbio’s RGX-121 Trial Achieves Major Milestone in Hunter Syndrome Treatment

The heart, like the stomach, wants a varied diet.

byLiliana Vida
February 22, 2024
in Pharmaceuticals, Small-Cap
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

Regenxbio Inc. (Nasdaq: RGNX) has announced significant progress in its Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II), commonly known as Hunter syndrome. The company revealed that the pivotal phase of the trial has successfully met its primary endpoint with statistical significance.

The topline results, presented at the 20th Annual WORLDSymposium™ by trial investigator Paul Harmatz, M.D. from UCSF Benioff Children’s Hospital, are highly promising. Kenneth T. Mills, President and CEO of REGENXBIO, expressed enthusiasm, stating, “The data from this pivotal trial supports that RGX-121 changes the course of the disease by restoring the missing gene in boys with Hunter syndrome and has the potential to significantly improve vital brain function for patients.”

The pivotal trial demonstrated that patients treated with RGX-121 achieved a remarkable reduction in cerebrospinal fluid (CSF) levels of D2S6, a key biomarker of brain disease activity, with an 86% median reduction approaching normal levels. Additionally, patients showed continued improvement in neurodevelopmental function, and many were able to discontinue standard-of-care intravenous enzyme replacement therapy (ERT) or remain ERT-naïve.

REGENXBIO plans to file a Biologics License Application (BLA) in 2024 using the accelerated approval pathway. The company aims to leverage CSF levels of D2S6 as a surrogate endpoint for accelerated approval, with potential approval anticipated as early as 2025.

The success of the RGX-121 trial represents a significant breakthrough in addressing the unmet medical needs of MPS II patients, offering hope for improved outcomes and a better quality of life. With these promising results, REGENXBIO is poised to make a meaningful impact in the treatment landscape for Hunter syndrome.

Next Post

BioNTech and Autolus Forge Strategic Partnership to Propel CAR-T Cell Therapy Pipeline

Related Posts

scientist

Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial

byLuca Blaumann
August 19, 2025
0

Strong weight reduction overshadowed by concerns over side effects Viking Therapeutics (VKTX) shares plummeted nearly 45% on Tuesday after the...

KULR Technology Group Reports Record Q2 Revenue and Expands Bitcoin Treasury Holdings

byLuca Blaumann
August 14, 2025
0

Frontier technology firm posts strong top-line growth, boosts BTC portfolio, and advances R&D in energy systems and robotics KULR Technology...

chemistry-2

Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development

byLuca Blaumann
August 14, 2025
0

Partnership leverages artificial intelligence to accelerate discovery of next-generation treatments for obesity and cardiometabolic diseases Eli Lilly (LLY) has entered...

Next Post
scientist-2

BioNTech and Autolus Forge Strategic Partnership to Propel CAR-T Cell Therapy Pipeline

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Casual Dining’s Comeback: Why Sit-Down Chains Are Beating Fast Casual

Intel Seeks More Equity Infusions Amid Mounting Financial Strains

Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial

Intel Shares Surge After $2 Billion SoftBank Investment

Strategy Expands Bitcoin Holdings With $51 Million Purchase

Based on Your Interest

Aerospace & Defense

Amphenol Expands Defense Portfolio With $1 Billion Trexon Acquisition

August 18, 2025
investing
Insurance

Buffett Bet Sends UnitedHealth Shares Soaring

August 18, 2025
Small-Cap

KULR Technology Group Reports Record Q2 Revenue and Expands Bitcoin Treasury Holdings

August 14, 2025

Recommended

Financial Services

Berkshire Hathaway Adds New Stakes Across Healthcare, Industrials, and Real Estate

August 14, 2025
Pharmaceuticals

Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development

August 14, 2025
Large-Cap

Ulta and Target to End Mini-Store Partnership in 2026

August 14, 2025
Airlines

Spirit Aviation Warns of Possible Collapse as Cash Runs Low

August 13, 2025
Large-Cap

Cava Shares Plunge as Chain Cuts Same-Store Sales Outlook

August 12, 2025
Stoxpo

Follow us on social media:

Highlights

  • Casual Dining’s Comeback: Why Sit-Down Chains Are Beating Fast Casual
  • Intel Seeks More Equity Infusions Amid Mounting Financial Strains
  • Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial
  • Intel Shares Surge After $2 Billion SoftBank Investment
  • Strategy Expands Bitcoin Holdings With $51 Million Purchase

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Casual Dining’s Comeback: Why Sit-Down Chains Are Beating Fast Casual

August 21, 2025

Intel Seeks More Equity Infusions Amid Mounting Financial Strains

August 20, 2025
scientist

Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial

August 19, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?